Jiangsu Maoxing Technology

Maoxing Biotech is a clinical-stage biotechnology company headquartered in Suzhou, China, dedicated to the development of next-generation "off-the-shelf" universal CAR-T (UCAR-T) therapies. The company leverages its proprietary CRISPR/Cas9 gene-editing platform to create allogeneic cell products that aim to be safer, more effective, and significantly more affordable than traditional autologous treatments. Maoxing's pipeline includes candidates targeting CD19 for B-cell malignancies and B7-H3 for solid tumors, specifically glioblastoma. By addressing the challenges of graft-versus-host disease and host-versus-graft rejection, the company seeks to provide readily available immunotherapy options for a broad range of cancer patients.